Objective-Previous studies demonstrated that apolipoprotein A-IV (apoA-IV) promotes apoB lipoprotein-mediated triglyceride (TG) secretion in transfected enterocytes and hepatoma cells; however, evidence for a role in lipid transport in vivo is lacking. Using mouse models, we explored the role of apoA-IV in hepatic very low density lipoprotein-mediated lipid efflux under conditions that promote hepatic steatosis. Approach and Results-Hepatic steatosis, induced by either high-fat diet or enhanced de novo lipogenesis caused by transgenic overexpression of SREBP-1a (SREBP-1a Tg ), was associated with up to a 43-fold induction of hepatic apoA-IV mRNA and protein levels. In both models, a positive linear correlation between hepatic TG content and apoA-IV mRNA abundance was observed (r 2 =0.8965). To examine whether induction of apoA-IV affected hepatic TG secretion, SREBP-1a
T he epidemic of obesity and associated metabolic syndrome has caused a rapid increase in the incidence of nonalcoholic fatty liver disease, which now affects approximately one third of adults in developed countries.
1,2 A predominant means by which the liver protects itself from excess lipid accumulation is the assembly and secretion of very low density lipoproteins (VLDLs). 1 Bulk triglyceride (TG) export from the liver can be increased by 2 nonexclusive mechanisms: assembly and secretion of a greater number of VLDL particles or secretion of larger VLDL particles containing an increased amount of core lipid. Although a broad understanding of the VLDL assembly pathway has emerged, the question of how the liver integrates particle number with particle size to achieve a given rate of hepatic lipid efflux is poorly understood. [3] [4] [5] One factor that may play a role in modulating apoB lipoprotein assembly and particle expansion is apolipoprotein A-IV (apoA-IV). ApoA-IV is a 46-kDa lipid-binding protein, which is expressed not only in the mammalian intestine but also in rodent liver. Since its discovery in 1977, apoA-IV has been ascribed a wide variety of functions in lipid metabolism and metabolic regulation. [6] [7] [8] [9] Perhaps the most notable characteristic of apoA-IV is the close association between active intestinal lipid absorption and the induction of intestinal apoA-IV gene expression. 10 The first direct functional connection between apoA-IV expression and bulk lipid transport was observed in a cultured pig intestinal epithelial cell model, in which transfection of apoA-IV constructs strongly enhanced transcellular TG transport, primarily by promoting lipoprotein particle expansion. 11, 12 Similar results were observed in transfected rat hepatoma cells, in which the impact of apoA-IV on apoB lipoprotein assembly was attributed to its ability to alter the trafficking kinetics of nascent apoB-containing lipoproteins by interacting with apoB in the secretory pathway. 13, 14 However, despite the considerable physiological and in vitro evidence linking apoA-IV and intestinal TG transport, a long-standing conundrum has been that no significant impact of genetic apoA-IV deficiency or transgenic (Tg) overexpression on intestinal lipid absorption and growth was observed in mouse models in vivo. 15, 16 In contrast to the intestine-an organ that possesses both excess absorptive capacity and robust adaptive mechanisms, which may mask subtle defects in lipid transport 17 -the liver is highly sensitive to signals that alter lipid metabolic pathways, as evidenced by the many genetic, hormonal, and dietary factors that contribute to nonalcoholic fatty liver disease. 1, 18 We, therefore, chose to explore the function of apoA-IV in the liver by assessing its impact on TG secretion under conditions of hepatic steatosis, induced by either feeding a high-fat and high-cholesterol diet or by unregulated de novo lipogenesis, caused by Tg expression of a constitutively active form of SREBP-1a. 19, 20 We found that, unlike in the intestine, apoA-IV deficiency and overexpression exert a powerful impact on hepatic TG secretion rate and lipid content, attributable to its ability to promote nascent VLDL particle expansion. These data provide the first evidence for a direct role of apoA-IV in modulating lipid transport, in vivo, and suggest that its expression can dramatically enhance VLDL-mediated hepatic TG efflux by promoting particle expansion without increasing the number of atherogenic apoB lipoprotein particles secreted by the liver.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Hepatic ApoA-IV Expression Is Increased in Steatosis
Two models of hepatic steatosis were used to assess the impact of cellular TG content on hepatic apoA-IV expression. In the first model, Tg expression of a constitutively active form of SREBP-1a (SREBP-1a Tg ) promotes the transcription of genes responsible for hepatic de novo lipogenesis. 19, 20 Because the transgene is under the control of the PEPCK promoter, feeding a low-carbohydrate diet further induces SREBP-1a and lipogenic gene expression, causing massive TG accumulation. 19 As shown in Figure 1A , SREBP-1a Tg mice displayed a 15-fold increase in liver TG content relative to wild-type (WT) littermates on the chow diet and a 35-fold relative increase on the low-carbohydrate diet. Under these conditions, apoA-IV mRNA abundance increased 18-and 43-fold, respectively ( Figure 1B) ; immunoblot analysis confirmed that this was accompanied by a corresponding increase in hepatic apoA-IV protein levels ( Figure 1C ). In the second model, hepatic steatosis was induced by feeding a high-fat and high-cholesterol diet to WT C57BL/6 mice. After 16 weeks on diet, liver TG content had increased 15-fold relative to chow-fed controls ( Figure 1D ) and apoA-IV mRNA abundance increased 27-fold ( Figure 1E) , with a corresponding increase in apoA-IV protein mass ( Figure 1F ). Analysis of all data from both models revealed a strong positive linear correlation (r 2 =0.8965) between hepatic TG content and apoA-IV mRNA abundance ( Figure 1G ). These data indicate that hepatic apoA-IV mRNA and protein levels are dramatically increased by conditions that promote hepatic TG accumulation and suggest that apoA-IV gene expression may be regulated either directly or indirectly by intracellular TG content.
ApoA-IV Deficiency in SREBP-1a
Tg Mice Reduces Hepatic TG Secretion Tg /A4-WT) littermates. As shown in Figure 2 , neither apoA-IV mRNA ( Figure 2A ) nor protein ( Figure 2B ) was detected in the livers of SREBP-1a
Tg /A4-KO mice. ApoA-IV deficiency produced a small reduction in plasma TG levels, consistent with previous reports, 16 although in this study the reduction did not reach statistical significance ( Figure 2C ). Mice were maintained on the low-carbohydrate diet for 3 weeks, and then hepatic TG secretion rates were measured after administration of Triton WR1339 (Triton) to block peripheral lipolysis. The absence of apoA-IV expression in the SREBP-1a
Tg /A4-KO mice significantly reduced plasma TG accumulation at times >30 minutes compared with the SREBP-1a
Tg /A4-WT control littermates ( Figure 2D ) and reduced the overall hepatic TG secretion rate by 24% ( Figure 2E ). Although there was a trend toward increased hepatic TG content in the SREBP-1a
Tg /A4-KO mice, this difference was not significant ( Figure 2F ). These data indicate that in the absence of apoA-IV, SREBP-1a
Tg mice were less efficient in secreting TG from the liver.
To explore the basis for the lower TG secretion rate in SREBP-1a
Tg /A4-KO mice, we first considered whether apoB secretion had been affected. SDS-PAGE and phosphorimager analysis of radiolabeled apoB in plasma VLDL revealed no differences in the amount of total secreted apoB protein ( Figure 3A and 3B), indicating that apoA-IV gene deletion did not change the number of secreted apoB-containing VLDL particles. We next analyzed the size distribution of VLDL isolated from the Triton block experiments using negative stain electron microscopy. 21 Although the presence of Triton in the plasma samples might be perturbing, others have assessed particle characteristics in postdetergent plasma by size exclusion chromatography and negative stain electron microscopy. [22] [23] [24] Visual inspection of representative images suggested that plasma VLDL from the SREBP-1a
Tg / A4-WT mice contained a greater proportion of larger lipoprotein particles compared with the SREBP-1a
Tg /A4-KO mice ( Figure 3C ). Indeed, systematic analysis of the particle size distribution revealed that the percentage of VLDL particles with diameters ≥120 nm was lower in SREBP-1a
Tg / A4-KO plasma ( Figure 3D and 3E). This finding suggests that VLDL particle expansion was impaired in the absence of apoA-IV expression.
Overexpression of Human ApoA-IV Increases Hepatic TG Secretion in SREBP-1a Tg Mice
Because apoA-IV deficiency appeared to decrease the rate of hepatic TG secretion by reducing VLDL particle size, we next explored whether overexpression of human apoA-IV in SREBP-1a Tg mouse liver would have the converse effect. Tg mice reduces nascent very low density lipoprotein (VLDL) particle diameter. Pooled blood samples were collected 180 minutes after Triton injection, and VLDL was isolated from plasma by ultracentrifugation, as described under Materials and Methods. A, Accumulation of 35 S-labeled newly synthesized and secreted apoB in terminal plasma. B, Relative phosphorimager units of total apoB (apoB100+B48) normalized to SB-Tg/A4-WT. C, VLDL visualized by negative stain electron microscopy (×49 000). D, Size distribution of VLDL particles; >500 particles were measured. E, Percentage of total VLDL particles ≥120 nm. Data in B were analyzed by unpaired Student t test (n=5). A4-KO indicates Apoa4 knockout; Tg, transgenic; and WT, wild type.
For this purpose, we generated a recombinant adenovirus expressing human apoA-IV (ad-huA4) and a control adenovirus expressing bacterial β-galactose (ad-LacZ). Infection of SREBP-1a
Tg mice with either ad-huA4 or ad-LacZ caused abundant hepatic expression of the respective proteins 3 days postinjection ( Figure 4A ). Mice receiving ad-huA4 also demonstrated an increase in plasma TG levels to ≈175 mg/dL, presumably attributable to increased VLDL secretion and/or inhibition of VLDL clearance. Studies with apoA-IV Tg mice, with overexpression predominantly in the intestine, also noted decreased lipolysis, possibly because of displacement of the lipoprotein lipase coactivator apoC-II from the TG-rich lipoprotein surface by apoA-IV. 15, 25, 26 To explore the impact of apoA-IV overexpression on the hepatic TG secretion rate, mice treated with ad-huA4 and adLacZ were administered Triton to block peripheral lipolysis and plasma TG accumulation was measured as a function of time. In SREBP-1a
Tg mice treated with ad-huA4, a 52% increase in the rate of TG secretion was observed relative to LacZ controls ( Figure 4C and 4D) . Because the expression of apoA-IV produced a dramatic increase in the rate and amount of TG secreted, we examined whether there was a corresponding decrease in hepatic lipid burden. For this purpose, mice were separately injected with ad-huA4 or ad-LacZ and 3 days postinjection, animals were euthanized and liver lipids measured. These data revealed a 38% decrease in the hepatic TG content of mice overexpressing huA4 compared with mice administered ad-LacZ ( Figure 4E) . A similar reduction in hepatic TG content was also observed in the animals that had been subjected to the Triton block analysis used in Figure 4C (data not shown).
To explore the basis of the enhanced TG secretion in the mice treated with ad-huA4, radiolabeled apoB in VLDL was isolated from terminal bleeds and quantitated by SDS-PAGE and phosphorimager analysis. As with the apoA-IV knockout experiments, no difference in the secretion of radiolabeled apoB was observed, indicating that overexpression of apoA-IV did not increase the number of VLDL particles secreted by the liver (Figure 5A and 5B). However, negative stain electron microscopy analysis of VLDL particles revealed that apoA-IV overexpression caused a 43% increase in the percentage of VLDL particles with diameters ≥120 nm ( Figure 5C-5E ). These data suggest that the increase in TG secretion and concomitant decrease in hepatic TG observed in mice overexpressing apoA-IV is because of secretion of larger, more TG-enriched apoB-containing VLDL, rather than a greater number of lipoprotein particles. It should be noted that the lipoprotein diameters observed in the control LacZ mice were smaller than those in the SB-Tg/A4-WT control mice in Figure 3 . This is likely attributable to the fact that the secretion of very large chylomicron-sized VLDL from SREBP1a
Tg mice is dependent on dysregulated de novo lipogenesis and hepatic lipid accretion. 20 Because the animals used for the adenovirus experiments were maintained on a chow diet Figure 4 were collected at the 180-minute time point. A, VLDL was isolated by ultracentrifugation, followed by immunoprecipitation with anti-apoB antibody, SDS-PAGE, and phosphorimager analysis. B, Relative phosphorimager units of total apoB (apoB100+B48) normalized to LacZ (n=4). C, Negative stain electron microscopy (×49 000) of pooled VLDL. D, Size distribution of VLDL particles; >500 particles were measured. E, Percentage of total VLDL particles ≥120 nm. Tg indicates transgenic.
(ie, intermediate steatosis), their lipoprotein particles were likely smaller than those that were maintained on the low-carbohydrate diet, which induces maximal steatosis ( Figure 1A) .
Recent studies have demonstrated that apoA-IV might impact apoB lipoprotein particle dynamics by modulating the expression of the microsomal triglyceride transfer protein (MTP). 27, 28 Hence, we specifically examined whether MTP mRNA or protein mass was affected by apoA-IV. As seen in Figure 6 , neither MTP mRNA nor protein abundance was affected by apoA-IV deficiency ( Figure 6A and 6C) or overexpression ( Figure 6B and 6D) . We next explored whether other genes with roles in hepatic lipid metabolism could account for the altered TG secretion observed in these studies. No changes in expression of genes responsible for de novo lipogenesis, fatty acid esterification, intracellular lipolysis, β-oxidation, or VLDL assembly were observed ( Figure III in the onlineonly Data Supplement), with the exception of DGAT1, where in both the A4-KO and in the ad-huA4 livers we observed a small (≈1.5-and 2-fold, respectively) but significant increase in mRNA abundance, relative to controls. Because this pattern of expression could not explain the observed changes in VLDL-TG secretion, particularly in the knockout situation, we suggest that this modest change in one lipogenic gene is not likely to be biologically relevant to the observed effects of apoA-IV on hepatic TG secretion and instead confirm the core conclusion that apoA-IV may directly impact the extent of VLDL lipidation.
Discussion
Although a broad spectrum of physiological functions has been proposed for apoA-IV, 29 a preponderance of evidence suggests that it plays a role in intestinal lipid absorption and chylomicron assembly. 9, [30] [31] [32] [33] Indeed, recent studies with cultured intestinal and hepatoma cells have established that apoA-IV expression increases bulk TG transport by enabling secretion of larger TG-rich lipoproteins. 12, 14 Nonetheless, elucidation of the specific role of apoA-IV in lipid transport in vivo has remained elusive, for studies with apoA-IV knockout and Tg mice found no gross abnormalities in dietary lipid absorption. 15, 16 In part, this may be attributable to the fact that the intestine possesses a large absorptive reserve capacity and robust compensatory cellular mechanisms, which can mask the impact of perturbed apoA-IV expression on lipid transport. However, in rodents, apoA-IV is also expressed in the liver. 34 In this organ, TG uptake, synthesis, and secretion is controlled by complex metabolic pathways and is regulated by multiple dietary and hormonal factors, such that even small changes in the relative rates of TG import and synthesis versus oxidation and secretion can rapidly lead to intracellular TG accumulation (steatosis) and inflammation (steatohepatitis). 1 We thus reasoned that examining the impact of altered apoA-IV expression on hepatic VLDL secretion and TG content could reveal an unequivocal metabolic phenotype with direct clinical relevance.
We, therefore, examined the impact of altering hepatic apoA-IV expression by genetic deletion and adenoviralinduced overexpression on VLDL-TG secretion and cellular TG content under conditions of hepatic steatosis caused by Tg expression of the constitutively active form of SREBP-1a. 19, 20 Using this approach, we not only observed that hepatic apoA-IV gene expression and protein levels are increased by conditions that promote hepatic TG accumulation but also, for the first time, have demonstrated an unequivocal metabolic phenotype directly related to apoA-IV expression: that is, genetic absence of apoA-IV reduces hepatic TG secretion and VLDL particle size, whereas adenoviral overexpression of human apoA-IV enhances VLDL-TG secretion, increases VLDL particle size, raises plasma TG levels, and reduces hepatic TG content. These data reveal that apoA-IV expression can exert a powerful impact on hepatic TG export, which is attributable to its ability to promote VLDL particle expansion within the secretory pathway.
The parallel increases in hepatic TG and apoA-IV mRNA content, which we observed in steatosis induced by increased lipogenesis and a high-fat and high-cholesterol diet, have been reported in other mouse models of steatosis. A 100-fold induction of hepatic apoA-IV mRNA was seen in suckling fatty liver dystrophy (fld) mice, which returned to baseline when liver TG content rapidly fell upon weaning. 35 Williams et al 36 also observed that a high-fat diet induces hepatic apoA-IV expression, although in their studies the effect was strain specific. The strong positive correlation between apoA-IV mRNA abundance (and in the current study, protein concentration) and hepatic TG content in all these models of steatosis implies that cellular TG or fatty acid accumulation may provide a specific signal for upregulating apoA-IV gene expression. In this regard, the mechanisms by which lipids regulate hepatic apoA-IV gene transcription are not well understood. [37] [38] [39] Recently, it was discovered that the endoplasmic reticulum (ER)-tethered, liver-specific transcription factor cAMP response elementbinding protein H is required for hepatic apoA-IV synthesis. 40, 41 Activation of cAMP response element-binding protein H requires translocation from ER to Golgi, proteolytic processing, and release of the active form into the nucleus. Although the exact metabolic cues that mediate this activation sequence are unknown, 41 cAMP response element-binding protein H expression is enhanced by a number of metabolic conditions, including fasting, insulin resistance, 42 and ER stress, 43 all of which also promote VLDL secretion. 44, 45 Thus, it is intriguing to consider that the MTPmediated movement of lipid across the ER membrane [46] [47] [48] or incorporation into nascent primordial particles in the ER 49 integrates apoA-IV gene expression with VLDL assembly, perhaps via cAMP response element-binding protein H production and/or processing, which then, in turn, serves as the specific signal that regulates apoA-IV transcription.
A possible issue compromising the interpretation of results using the A4-KO mouse is the reduction in expression of the neighboring gene, Apoc3. 16 Because apoC-III is a lipase inhibitor, its lower abundance affects TG-rich lipoprotein clearance, as was observed in previous studies 16 and in Figure 2D , in which a nonsignificant decrease in plasma TG was observed in SREBP-1a
Tg /A4-KO mice. ApoC-III overexpression, both in hepatoma cells and in vivo, is also associated with enhanced VLDL-TG production. 50, 51 In contrast, studies in Apoc3 knockout mice failed to observe reductions in hepatic TG secretion, even after feeding a high-fat diet. 52, 53 Hence, it is unlikely that the decreased hepatic VLDL-TG secretion associated with apoA-IV deficiency observed in these studies is the result of decreased apoC-III expression. This conclusion was supported by the 52% increase in TG secretion observed when apoA-IV was selectively overexpressed using a recombinant adenovirus ( Figure 4D ). Although the apoA-IV/C-III effects on lipolysis may also complicate interpretation of the impact of production versus clearance on steady-state plasma TG levels, the use of the Triton block method clearly demonstrates an impact of apoA-IV on hepatic VLDL-TG production. Because these changes were not accompanied by altered apoB secretion, the implication is that modification of particle size and not particle number was the basis for the observed effects. This conclusion was supported by direct analysis of particle diameters from post-Triton block plasma in which, based on the changes in TG values between the 0-and 180-minute time points, ≈90% to 95% of the TG-rich particles present were produced under conditions of lipase inhibition.
Two mechanisms have been proposed to explain how apoA-IV facilitates the assembly of larger lipoprotein particles. Because only a single molecule of apoB is incorporated into each nascent lipid particle in the first step of TG-rich lipoprotein assembly, the expansion of the TG core in the second stage of assembly exposes surface lipids to the aqueous milieu, which decreases their free energy of stabilization. 54, 55 Because the interfacial properties of apoA-IV are ideally suited to stabilizing expanding lipid interfaces, 56, 57 we have proposed that adsorption of apoA-IV molecules to the expanding particle surface renders core lipid incorporation more thermodynamically favorable, which thus facilitates particle growth. 58 However, we have also presented evidence in cultured rat hepatoma cells that a protein-protein interaction between apoA-IV and a domain in the amino terminus of apoB delays the secretory trafficking of nascent TG-rich lipoproteins in a manner that enables their cores to become more fully lipidated before final secretion.
14 These mechanisms are not mutually exclusive.
Another possible explanation for the impact of apoA-IV on VLDL-TG secretion centers on its ability to modulate MTP expression or the expression of other genes involved in hepatic lipid metabolism. Previous studies demonstrated that apoA-IV stimulates MTP expression in both intestine and Huh7 hepatoma cells via the regulation of the transcription factors FoxA2 and FoxO1. 27, 28 However, in the current study, we failed to observe a similar relationship between apoA-IV and MTP expression ( Figure 6 ). A further exploration of genes involved in lipid metabolism also failed to identify a pattern of gene expression that could account for the enhanced TG secretion associated with apoA-IV expression ( Figure III in the online-only Data Supplement). Again, these data suggest that apoA-IV may play a direct role in the modulation of apoB lipoprotein particle expansion and TG transport.
In summary, we have demonstrated in 2 models of liver steatosis that hepatic TG accumulation and apoA-IV RNA levels increase in parallel and that adenoviral-mediated hepatic apoA-IV expression increases the rate of hepatic VLDL-TG transport and reduces liver TG content by enabling the assembly of larger apoB-containing lipoprotein particles, rather than by increasing the number of particles that are secreted. Because efficient TG export is an important means by which the liver protects itself from toxic accumulation of intracellular lipids, these data suggest that increasing hepatic apoA-IV expression by dietary, pharmacological, or biological approaches could constitute a novel strategy for treating nonalcoholic fatty liver disease, without raising the long-term risk of atherosclerotic cardiovascular heart disease attributable to secretion of increased numbers of atherogenic apoB-containing lipoproteins. 
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